COMMUNIQUÉS West-GlobeNewswire

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
16/02/2024
No Impact on Cash, Cash Equivalents and Marketable Investments, Cash Runway or Business Operations Company Targeting On or Before March 14, 2024 to File Amended Financial Statements and Report Fourth Quarter and Full [...]
Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
16/02/2024
Site initiation completed for first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, Feb. 16, 2024 (GLOBE NEWSWIRE [...]
Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results
16/02/2024
Quarterly investor conference call and webcast scheduled for Tuesday, February 27 at 8:30 a.m. ET WESTLAKE VILLAGE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial- [...]
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
16/02/2024
FREEHOLD, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell” or the “Company”), a clinical-stage biotech company focused on developing and commercializing new [...]
Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share
16/02/2024
SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced it has entered into a [...]
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
16/02/2024
EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the [...]
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
16/02/2024
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE [...]
Annual General Meeting in ALK-Abelló A/S on 14 March 2024
16/02/2024
ALK ( ALKB:DC / OMX: ALK B / AKBLF ): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 14 March 2024 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark. The agenda of the [...]
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
16/02/2024
NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter and full year ended December 31 [...]
L’hôpital spécialisé et centre de recherche King Faisal confirme sa position de leader mondial et régional de la santé
16/02/2024
RIYAD, Arabie Saoudite, 16 févr. 2024 (GLOBE NEWSWIRE) -- Pour la deuxième année consécutive, l’hôpital spécialisé et centre de recherche King Faisal, ci-après « KFSH&RC » pour King Faisal Specialist Hospital & [...]
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/02/2024
WATERTOWN, Mass., Feb. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal [...]
Pharvaris Announces Extraordinary Meeting of Shareholders
16/02/2024
ZUG, Switzerland , Feb. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks [...]
Vistin Pharma ASA: Key information relating to the proposed cash dividend
16/02/2024
The Board of Directors of Vistin Pharma ASA plans to propose to distribute a cash dividend of total NOK 1.00 per share, to be paid partly in June and November, for the accounting year of 2023. The formal decision [...]
Smart Immune appoints key new members to its Board of Directors
16/02/2024
Smart Immune appoints key new members to its Board of Directors PARIS, France, 16 February 2024 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T cell progenitor therapy [...]
Vistin Pharma ASA: Fourth quarter and preliminary 2023 financial results
16/02/2024
Oslo, Norway, 16 th of February 2024 Vistin Pharma ASA (Vistin Pharma, OSE: VISTN) today announces the financial results for the fourth quarter of 2023. Vistin delivers another strong quarter with a 12% revenue growth [...]
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
16/02/2024
Japan first in the world to approve Dupixent ® for chronic spontaneous urticaria (CSU) Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the [...]
Communiqué de presse : Le Japon est le premier pays dans le monde à approuver Dupixent® pour le traitement de l’urticaire chronique spontanée
16/02/2024
Le Japon est le premier pays dans le monde à approuver Dupixent ® pour le traitement de l’urticaire chronique spontanée L’approbation est fondée essentiellement sur les résultats d’un essai de phase III ayant montré que [...]
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
16/02/2024
Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dupixent globally [...]
Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office
16/02/2024
Tokyo, Japan and Cambridge, UK, 16 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), today announces that at a meeting held on 15 February 2024, its Board of Directors resolved to [...]

Pages